I-Gefitinib CAS 184475-35-2 Ubumsulwa >99.5% (HPLC)
I-Shanghai Ruifu Chemical Co., Ltd. ingumkhiqizi ohamba phambili we-Gefitinib (CAS: 184475-35-2) enekhwalithi ephezulu.I-Ruifu Chemical inganikeza ukulethwa komhlaba wonke, intengo encintisanayo, isevisi enhle kakhulu, amanani amancane kanye nenqwaba etholakalayo.Thenga i-Gefitinib kanye nabaphakathi,Please contact: alvin@ruifuchem.com
| Igama Lekhemikhali | I-Gefitinib |
| Omqondofana | I-Gefitinib Free Base;Iressa;I-ZD1839;I-ZD-1839;N-(3-Chloro-4-Fluorophenyl)-7-Methoxy-6-(3-Morpholinopropoxy)quinazolin-4-Amine;N-(3-Chloro-4-Fluorophenyl)-7-Methoxy-6-[3-(4-Morpholinyl) propoxy]-4-Quinazolinamine |
| Isimo Sesitoko | Ku-Stock, Commercial Production |
| Inombolo ye-CAS | 184475-35-2 |
| I-Molecular Formula | I-C22H24ClFN4O3 |
| Isisindo samangqamuzana | 446.91 g/mol |
| I-Melting Point | 194.0 ukuze 198.0 ℃ |
| Ukuminyana | 1.322±0.06 g/cm3 |
| Ukuncibilika kwamanzi | Ayincibiliki Emanzini |
| Ukuncibilika | I-Soluble ku-DMSO |
| Isikhathi Sokugcina. | Ukushisa Kwegumbi |
| Ukuthumela ngomkhumbi | I-ambient |
| I-COA ne-MSDS | Iyatholakala |
| Umsuka | Shanghai, China |
| Ibhrendi | I-Ruifu Chemical |
| Izinto | Amazinga Wokuhlola | Imiphumela |
| Ukubukeka | Impushana Emhlophe Kuya Kumhlophe | Iyahambisana |
| Ukulahlekelwa Ekumisweni | <0.50% | 0.13% |
| Izinsalela ekushiseni | <0.20% | 0.06% |
| Ukungcola Okukodwa | <0.10% | 0.09% |
| Ukungcola Okuphelele | <0.50% | 0.20% |
| Izinsimbi Ezisindayo (Pb) | ≤10ppm | <10ppm |
| Ukuhlanzeka / Indlela Yokuhlaziya | >99.5% (HPLC) | 99.80% |
| I-Infrared Spectrum | Ihambisana Nesakhiwo | Iyahambisana |
| 1H NMR Spectrum | Ihambisana Nesakhiwo | Iyahambisana |
| Isiphetho | Umkhiqizo uhloliwe futhi uthobela imininingwane enikeziwe | |
Iphakheji:Ibhodlela eliFluorinated, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwezidingo zekhasimende.
Isimo Sesitoreji:Gcina isitsha sivalwe ngokuqinile futhi usigcine endaweni epholile, eyomile futhi enomoya omuhle kude nezinto ezingahambelani.Vikela ekukhanyeni nakumswakama.
Ukuthumela:Zilethe emhlabeni wonke ngendiza, yi-FedEx/DHL Express.Nikeza ukulethwa okusheshayo nokuthembekile.
Ayisetshenziswa kubantu.Ayisetshenziselwa ukuxilonga noma ukwelashwa.Ukusetshenziswa kocwaningo lwe-in vitro kuphela.
Ayikho imikhiqizo ezonikezwa amazwe lapho lokhu kungase kungqubuzane namalungelo obunikazi akhona.Kodwa-ke umthwalo wokugcina ulele kuMthengi.
Indlela Yokuthenga?Sicela uxhumaneDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
Iminyaka engu-15 Yokuhlangenwe nakho?Sinesipiliyoni seminyaka engaphezu kwe-15 ekwakhiweni nasekuthumeleni kwamanye amazwe uhla olubanzi lwezinga eliphezulu lokuxhumanisa imithi noma amakhemikhali amahle.
Izimakethe Eziyinhloko?Thengisa emakethe yasekhaya, eNyakatho Melika, eYurophu, eNdiya, eKorea, eJapane, e-Australia, njll.
Izinzuzo?Ikhwalithi ephezulu, intengo ethengekayo, izinsizakalo ezichwepheshile nokusekelwa kobuchwepheshe, ukulethwa okusheshayo.
IkhwalithiIsiqiniseko?Isistimu yokulawula ikhwalithi eqinile.Imishini yobuchwepheshe yokuhlaziya ifaka i-NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, NOMA, KF, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, njll.
Amasampula?Imikhiqizo eminingi inikeza amasampula wamahhala wokuhlolwa kwekhwalithi, izindleko zokuthumela kufanele zikhokhelwe amakhasimende.
Ukuhlolwa Kwemboni?Wamukelekile ekucwaningweni kwemboni.Sicela wenze i-aphoyintimenti kusengaphambili.
I-MOQ?Ayikho i-MOQ.I-oda elincane liyamukeleka.
Isikhathi sokuthumela? Uma kungaphakathi kwesitoko, ukulethwa kwezinsuku ezintathu kuqinisekisiwe.
Ezokuthutha?By Express (FedEx, DHL), by Air, by Sea.
Amadokhumenti?Ngemuva kwenkonzo yokuthengisa: I-COA, i-MOA, i-ROS, i-MSDS, njll.
Custom Synthesis?Ingahlinzeka ngezinsizakalo zokwenziwa ngokwezifiso ukuze zilingane kangcono nezidingo zakho zocwaningo.
Imigomo Yokukhokha?I-invoyisi ye-Proforma izothunyelwa kuqala ngemva kokuqinisekiswa kwe-oda, kufakwe nemininingwane yethu yasebhange.Inkokhelo nge-T/T (Telex Transfer), PayPal, Western Union, njll.
| Incazelo Yokuphepha | 24/25 - Gwema ukuthintana nesikhumba namehlo. |
| Ikhodi ye-HS | 2934999099 |
I-Gefitinib (i-CAS: 184475-35-2) iyisidakamizwa esihloswe kakhulu sokulwa nesimila esakhiwe yi-AstraZeneca, UK.Uwumuthi wokuqala ohlosiwe wamangqamuzana wokwelapha umdlavuza wamaphaphu wamangqamuzana ongewona omncane.Isebenza ngokuvimbela ngokukhetha indlela yokudlulisa isignali ye-epidermal growth factor receptor tyrosine kinase (EGFR-TK).I-Epidermal growth factor (EGF) i-polypeptide enesisindo samangqamuzana esihlobene esingu-6.45 × 103, esingahlangana ne-epidermal growth factor receptor (EGFR) kulwelwesi lweseli oluqondiwe ukuze kukhiqizwe imiphumela yezinto eziphilayo.I-EGFR iyisamukeli sohlobo lwe-tyrosine kinase (TK).Uma ibophezela ku-EGF, ingakhuthaza ukusebenza kwe-TK emzimbeni womamukeli, okuholela ekutheni i-autophosphorylation yezinsalela ze-receptor tyrosine, inikeze amasignali okuhlukanisa okuqhubekayo kumaseli, okubangela ukwanda kwamaseli nokuhlukaniswa.I-EGFR igcwele ezicutshini zomuntu futhi ibonakala kakhulu ezimila eziyingozi.Ngokuvimbela indlela yokusayina ye-EGFR endaweni yeseli, i-gefitinib ivimbela ukukhula kwesimila, i-metastasis kanye ne-angiogenesis, futhi ingadala i-apoptosis yamaseli wesimila.Ngo-Agasti 2002, i-gefitinib yaqala ukukhangiswa e-Japan njengendlela yokwelapha yomugqa wokuqala yomdlavuza wamaphaphu ongewona omncane ngaphansi kwegama lokuhweba elithi Iressa.NgoMeyi 2003, i-US Food and Drug Administration yagunyaza i-gefitinib njenge-monotherapy yomugqa wesithathu yeziguli ezinomdlavuza wamaphaphu ongewona omncane wamangqamuzana ezazingasebenzi ngemithi elwa nomdlavuza esekelwe ku-platinum kanye ne-docetaxel chemotherapy.Njengamanje, isigunyazwe yi-Australia, Japan, Argentina, Singapore kanye neNingizimu Korea ukuze kwelashwe umdlavuza wamaphaphu ongewona omncane omncane.Ngomhla zingama-28 kuNhlolanja wezi-2005, i-China Food and Drug Administration igunyaze i-gefitinib yokwelapha umdlavuza wamaphaphu wamaphaphu osethuthuke endaweni noma ongewona omncane we-metastatic (NSCLC) owawuthole ukwelashwa ngamakhemikhali ngaphambilini.Okwamanje ayigunyaziwe ukuthi isetshenziswe njengokwelashwa komugqa wokuqala we-NSCLC ethuthukisiwe.Ngomhla zi-1 kuJulayi, 2009, i-European Medicines Agency yagunyaza ngokusemthethweni i-gefitinib yomugqa wokuqala, umugqa wesibili kanye nokwelashwa komugqa wesithathu womdlavuza wamaphaphu othuthukisiwe wasendaweni noma ongewona omncane we-metastatic nokuguqulwa kofuzo kwe-EGFR kubantu abadala.
